Cadrenal Therapeutics (NASDAQ:CVKD – Get Free Report) issued its earnings results on Monday. The company reported ($0.31) EPS for the quarter, topping the consensus estimate of ($0.91) by $0.60, FiscalAI reports.
Cadrenal Therapeutics Stock Up 4.3%
CVKD stock traded up $0.06 during midday trading on Tuesday, hitting $1.46. 6,698 shares of the company traded hands, compared to its average volume of 183,493. The stock has a market capitalization of $5.21 million, a price-to-earnings ratio of -0.29 and a beta of 1.94. Cadrenal Therapeutics has a twelve month low of $0.82 and a twelve month high of $12.50. The business has a 50 day simple moving average of $1.09 and a 200-day simple moving average of $3.61.
Wall Street Analyst Weigh In
Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Cadrenal Therapeutics in a research report on Thursday, October 15th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Cadrenal Therapeutics currently has an average rating of “Hold” and a consensus target price of $13.00.
Cadrenal Therapeutics Company Profile
Cadrenal Therapeutics is a clinical-stage biopharmaceutical company developing treatments to prevent blood clots in people with cardiovascular conditions that require long-term anticoagulation. Its pipeline centers on tecarfarin, an investigational oral anticoagulant being developed as a potential alternative to warfarin. Tecarfarin is designed to be processed through a different metabolic pathway than warfarin and is being studied for patients with needs such as mechanical heart valves and end-stage renal disease.
Read More
- Five stocks we like better than Cadrenal Therapeutics
- Tyson Foods’ Earnings Beat Hides a Warning for Consumer Staples Dividend Investors
- 3 Stocks in an Overlooked Corner of Infrastructure With Hundreds of Billions at Stake
- Tyson Foods’ 10% Surge Puts a Breakout in Sight, But Wall Street Remains Cautious
- Microsoft’s Outage Barely Moved Its Stock, But a Bigger Risk May Be Building
Receive News & Ratings for Cadrenal Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cadrenal Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
